Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 79 clinical trials
Featured trial
A Study Evaluating Safety and Tolerability and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

neoplasm (MPN) or chronic myelomonocytic leukemia (CMML).

essential thrombocythemia
chronic myelomonocytic leukemia
ruxolitinib
bone marrow procedure
myelofibrosis
  • 45 views
  • 25 May, 2022
  • 36 locations
Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)

The investigators hypothesize that long-term disease-free survival (DFS) in patients with JMML can be achieved with a treatment of busulfan (BU), cyclophosphamide (CY) and melphalan (L-PAM) followed by hematopoietic cell transplantation (HCT).

cell transplantation
monocytosis
melphalan
ejection fraction
cyclophosphamide
  • 4 views
  • 30 Apr, 2022
  • 1 location
Umbilical Cord Blood Transfusion in Consolidation Therapy of Elderly Patients With Acute Myeloid Leukemia

After complete remission, elderly AML patients cannot tolerate hematopoietic stem cell transplantation and standard-dose consolidation chemotherapy, and the 5-year survival rate is around 10%. Therefore, it is necessary to explore treatment strategy that can support chemotherapy or improve immunity. Umbilical cord blood is rich in hematopoietic stem cells and immune …

  • 0 views
  • 01 Sep, 2021
  • 2 locations
Azacitidine and Homoharringtonine in JMML

Juvenile myelomonocytic leukemia (JMML) has a poor prognosis in general, with hematopoietic stem cell transplant (HSCT) remaining the standard of care for cure. Azacitidine and homoharringtonine

myeloid leukemia
azacitidine
refractory acute myeloid leukemia (aml)
  • 0 views
  • 25 Jan, 2021
  • 1 location
Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML

Multicenter, randomized, open-label, crossover PK study of ASTX727 versus IV decitabine. Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive the ASTX727 tablet Daily5 in Cycle 1 followed by IV decitabine 20 mg/m^2 Daily5 in Cycle 2, or the converse order. After completion of …

myelomonocytic leukemia
secondary acute myeloid leukemia
conjugated bilirubin
secondary aml
leukemia
  • 283 views
  • 02 Mar, 2022
  • 38 locations
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

The purpose of this study is to determine the safety, tolerability, maximum tolerated doses (MTDs) and recommended Phase 2 doses (RP2Ds) of JNJ-74856665 as monotherapy and/or in combinations.

cell transplantation
myelomonocytic leukemia
human chorionic gonadotropin
lenalidomide
cytarabine
  • 1 views
  • 06 May, 2022
  • 20 locations
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG (GRAPPA)

Post-transplantation cyclophosphamide (PTCY) has become increasingly popular in the haploidentical HCT setting because it overcomes the HLA-mismatch barrier and levels GVHD risk. This advantage may also prove useful in the context of unrelated donor (UD) transplantation. GVHD prophylaxis for matched unrelated donor hematopoietic cell transplantation (alloHCT) in Europe is mainly …

  • 0 views
  • 15 Apr, 2022
  • 3 locations
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who have received standard therapy

IDH2
hematologic malignancy
blast cells
  • 0 views
  • 11 May, 2022
  • 35 locations
Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations

This is an open-label, nonrandomized phase 2 trial to assess the efficacy of cobimetinib in RAS pathway activated CMML. All eligible patients will be treated daily with cobimetinib in 28-day cycles. Cobimetinib will be administered for three weeks followed by a one week break prior to the start of the …

  • 0 views
  • 07 Nov, 2021
  • 1 location
Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion

This study is to find out if treating Chronic Myelomonocytic Leukemia (CMML) with a study drug (ruxolitinib) can improve outcomes of patients with CMML.

myeloproliferative disorder
chronic myelomonocytic leukemia
  • 99 views
  • 14 May, 2022
  • 4 locations